Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43


Epidermal Growth Factor and Granulocyte Colony Stimulating Factor Signaling Are Synergistic for Hematopoietic Regeneration.

Piryani SO, Kam AYF, Kliassov EG, Chen BJ, Spector NL, Chute JP, Hsu DS, Chao NJ, Doan PL.

Stem Cells. 2018 Feb;36(2):252-264. doi: 10.1002/stem.2731. Epub 2017 Nov 10.


A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo.

Crowe LB, Hughes PF, Alcorta DA, Osada T, Smith AP, Totzke J, Loiselle DR, Lutz ID, Gargesha M, Roy D, Roques J, Darr D, Lyerly HK, Spector NL, Haystead TAJ.

ACS Chem Biol. 2017 Apr 21;12(4):1047-1055. doi: 10.1021/acschembio.7b00006. Epub 2017 Feb 23.


X-Ray Psoralen Activated Cancer Therapy (X-PACT).

Oldham M, Yoon P, Fathi Z, Beyer WF, Adamson J, Liu L, Alcorta D, Xia W, Osada T, Liu C, Yang XY, Dodd RD, Herndon JE 2nd, Meng B, Kirsch DG, Lyerly HK, Dewhirst MW, Fecci P, Walder H, Spector NL.

PLoS One. 2016 Sep 1;11(9):e0162078. doi: 10.1371/journal.pone.0162078. eCollection 2016.


Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.

Spector NL, Robertson FC, Bacus S, Blackwell K, Smith DA, Glenn K, Cartee L, Harris J, Kimbrough CL, Gittelman M, Avisar E, Beitsch P, Koch KM.

PLoS One. 2015 Nov 16;10(11):e0142845. doi: 10.1371/journal.pone.0142845. eCollection 2015.


CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers.

Sutton LM, Geradts J, Hamilton EP, Havlin KA, Kimmick GG, Marcom PK, Spector NL, Watson M, Rabin DU, Bruno TO, Noe A, Miller S, Subramaniam C, Layton S, Grichnik K.

J Natl Compr Canc Netw. 2015 Aug;13(8):1005-11.


Identification of an allosteric small-molecule inhibitor selective for the inducible form of heat shock protein 70.

Howe MK, Bodoor K, Carlson DA, Hughes PF, Alwarawrah Y, Loiselle DR, Jaeger AM, Darr DB, Jordan JL, Hunter LM, Molzberger ET, Gobillot TA, Thiele DJ, Brodsky JL, Spector NL, Haystead TA.

Chem Biol. 2014 Dec 18;21(12):1648-59. doi: 10.1016/j.chembiol.2014.10.016. Epub 2014 Dec 11.


Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis.

Xia W, Gooden D, Liu L, Zhao S, Soderblom EJ, Toone EJ, Beyer WF Jr, Walder H, Spector NL.

PLoS One. 2014 Feb 14;9(2):e88983. doi: 10.1371/journal.pone.0088983. eCollection 2014.


Pertuzumab protects the achilles' heel of trastuzumab--emtansine.

Gwin WR, Spector NL.

Clin Cancer Res. 2014 Jan 15;20(2):278-80. doi: 10.1158/1078-0432.CCR-13-2626. Epub 2013 Nov 15.


An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.


Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.

Barrott JJ, Hughes PF, Osada T, Yang XY, Hartman ZC, Loiselle DR, Spector NL, Neckers L, Rajaram N, Hu F, Ramanujam N, Vaidyanathan G, Zalutsky MR, Lyerly HK, Haystead TA.

Chem Biol. 2013 Sep 19;20(9):1187-97. doi: 10.1016/j.chembiol.2013.08.004. Epub 2013 Sep 12.


A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.

Kurokawa M, Kim J, Geradts J, Matsuura K, Liu L, Ran X, Xia W, Ribar TJ, Henao R, Dewhirst MW, Kim WJ, Lucas JE, Wang S, Spector NL, Kornbluth S.

Sci Signal. 2013 May 7;6(274):ra32. doi: 10.1126/scisignal.2003741.


Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.

Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, Lyerly HK.

Breast Cancer Res. 2012 Apr 17;14(2):R62.


Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, Mao Y, He J, Wulfkuhle JD, Petricoin EF 3rd, Osada T, Yang XY, Hartman ZC, Clay TM, Blackwell KL, Lyerly HK, Spector NL.

Mol Cancer Ther. 2011 Aug;10(8):1367-74. doi: 10.1158/1535-7163.MCT-10-0991. Epub 2011 Jun 14.


Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.

Xia W, Bacus S, Husain I, Liu L, Zhao S, Liu Z, Moseley MA 3rd, Thompson JW, Chen FL, Koch KM, Spector NL.

Mol Cancer Ther. 2010 Feb;9(2):292-9. doi: 10.1158/1535-7163.MCT-09-1041. Epub 2010 Feb 2.


Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. doi: 10.1200/JCO.2009.22.1507. Epub 2009 Nov 2. Review.


Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.

Chen FL, Xia W, Spector NL.

Clin Cancer Res. 2008 Nov 1;14(21):6730-4. doi: 10.1158/1078-0432.CCR-08-0581. Review.


Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.

Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL.

J Clin Oncol. 2008 Mar 1;26(7):1066-72. doi: 10.1200/JCO.2007.13.9949. Epub 2008 Jan 22.


A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.

Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, Milanezi F, Lyass L, Amariglio N, Jacob-Hirsch J, Ben-Chetrit N, Tarcic G, Lindzen M, Avraham R, Liao YC, Trusk P, Lyass A, Rechavi G, Spector NL, Lo SH, Schmitt F, Bacus SS, Yarden Y.

Nat Cell Biol. 2007 Aug;9(8):961-9. Epub 2007 Jul 22.


Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells.

Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, Hill JE, Xia W, Seger R, Bacus SS.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10607-12. Epub 2007 Jun 7.


Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.

Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, Pry K, Westlund R, Stein SH, Spector NL.

Cancer Res. 2007 Feb 1;67(3):1170-5.


Delivery of a healthy baby after first-trimester maternal exposure to lapatinib.

Kelly H, Graham M, Humes E, Dorflinger LJ, Boggess KA, O'Neil BH, Harris J, Spector NL, Dees EC.

Clin Breast Cancer. 2006 Oct;7(4):339-41.


A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.

Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800. Epub 2006 May 8.


Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.

Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL.

Cancer Res. 2006 Feb 1;66(3):1640-7.


The era of ErbB-receptor-targeted therapies: advances toward personalized medicine.

Bacus S, Spector NL, Yarden Y.

Per Med. 2005 Nov;2(4):301-315. doi: 10.2217/17410541.2.4.301.


Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL.

J Clin Oncol. 2005 Aug 10;23(23):5305-13. Epub 2005 Jun 13.


Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S.

J Clin Oncol. 2005 Apr 10;23(11):2502-12. Epub 2005 Jan 31.


Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.

Bence AK, Anderson EB, Halepota MA, Doukas MA, DeSimone PA, Davis GA, Smith DA, Koch KM, Stead AG, Mangum S, Bowen CJ, Spector NL, Hsieh S, Adams VR.

Invest New Drugs. 2005 Jan;23(1):39-49.


A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.

Czito BG, Hong TJ, Cohen DP, Tyler DS, Lee CG, Anscher MS, Ludwig KA, Seigler HF, Mantyh C, Morse MA, Lockhart AC, Petros WP, Honeycutt W, Spector NL, Ertel PJ, Mangum SG, Hurwitz HI.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):779-85.


Concurrent exposure to heat shock and H7 synergizes to trigger breast cancer cell apoptosis while sparing normal cells.

Xia W, Hardy L, Liu L, Zhao S, Goodman M, Voellmy R, Spector NL.

Breast Cancer Res Treat. 2003 Feb;77(3):233-43.


Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.

Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.

Oncogene. 2002 Sep 12;21(41):6255-63.


Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine.

Xia W, Spector S, Hardy L, Zhao S, Saluk A, Alemane L, Spector NL.

Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7494-9.


Sensitization of tumor cells to fas killing through overexpression of heat-shock transcription factor 1.

Xia W, Voellmy R, Spector NL.

J Cell Physiol. 2000 Jun;183(3):425-31.


Truncation of Sp1 transcription factor by myeloblastin in undifferentiated HL60 cells.

Rao J, Zhang F, Donnelly RJ, Spector NL, Studzinski GP.

J Cell Physiol. 1998 May;175(2):121-8.


Activation signals regulate heat shock transcription factor 1 in human B lymphocytes.

Hardy L, Goodman M, Vasquez A, Chauhan D, Anderson KC, Voellmy R, Spector NL.

J Cell Physiol. 1997 Mar;170(3):235-40.


28-kDa mammalian heat shock protein, a novel substrate of a growth regulatory protease involved in differentiation of human leukemia cells.

Spector NL, Hardy L, Ryan C, Miller WH Jr, Humes JL, Nadler LM, Luedke E.

J Biol Chem. 1995 Jan 20;270(3):1003-6.


Regulation of the 28 kDa heat shock protein by retinoic acid during differentiation of human leukemic HL-60 cells.

Spector NL, Mehlen P, Ryan C, Hardy L, Samson W, Levine H, Nadler LM, Fabre N, Arrigo AP.

FEBS Lett. 1994 Jan 10;337(2):184-8.


Heat shock protein is a unique marker of growth arrest during macrophage differentiation of HL-60 cells.

Spector NL, Ryan C, Samson W, Levine H, Nadler LM, Arrigo AP.

J Cell Physiol. 1993 Sep;156(3):619-25.


Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.

Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Bl├Ąttler WA, Epstein CL, et al.

J Clin Oncol. 1993 Apr;11(4):726-37.


Growth arrest of human B lymphocytes is accompanied by induction of the low molecular weight mammalian heat shock protein (Hsp28).

Spector NL, Samson W, Ryan C, Gribben J, Urba W, Welch WJ, Nadler LM.

J Immunol. 1992 Mar 15;148(6):1668-73.


Activation primes human B lymphocytes to respond to heat shock.

Spector NL, Freedman AS, Freeman G, Segil J, Whitman JF, Welch WJ, Nadler LM.

J Exp Med. 1989 Nov 1;170(5):1763-8.


Radioimmunoassay for desmethylimipramine.

Spector S, Spector NL, Almeida MP Jr.

Psychopharmacol Commun. 1975;1(4):421-9.


Supplemental Content

Loading ...
Support Center